Trending: SpaceX propulsion guru Tom Mueller looks ahead to Raptor rocket engines for Mars

Hans Bishop
Juno Therapeutics CEO Hans Bishop speaking at the 2016 GeekWire Summit. (GeekWire Photo / Dan DeLong)

Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s $9 billion acquisition by biotech giant Celgene, he told GeekWire on Tuesday. Bishop has also joined Celgene’s board of directors.

Ann Lee. (Juno Photo)

Bishop helped found Juno when it spun out of the Fred Hutchinson Cancer Research Center in 2013. Over five years, he grew the company into an innovative biotech star that employed more than 500 people at the time it was acquired.

The company has made no official announcement of his departure. Bishop broke the news that he is no longer Juno’s CEO in an interview following the Pacific Science Center’s annual Innovation Breakfast, where he also spoke about the state of immunotherapy and the need to bring more young people into the sciences. A company spokesperson later confirmed his departure.

Ann Lee, formerly Juno’s EVP of technical operations, is taking over Celgene’s Seattle operations as its new regional site lead, the spokesperson said. Lee will lead the former Juno operations in the Seattle area as well as Celgene’s Seattle office, which predates the acquisition.

“The amount of research that’s going on in the field — immunotherapy in the broader sense — is just growing and growing,” Bishop told GeekWire at the event. “There are more different compounds, there are more different kinds of cells that we’re looking at, so the investment in the field is just accelerating.”

Former Juno CEO Hans Bishop (left) speaking to VP of Research and Receptor Discovery Francois Vigneault inside his lab. (GeekWire Photo / Kurt Schlosser)

Bishop declined to comment on Juno or Celgene’s work, citing his new role as a director of the company. When it was acquired, Juno was one of the top CAR T immunotherapy contenders in the world. In September, it opened a new, custom-designed headquarters in Seattle’s South Lake Union neighborhood.

Celgene will now continue to develop Juno’s unique CAR T immunotherapies, which genetically reprogram a patient’s immune cells to find and destroy cancer

At the time the acquisition was announced, Juno and Celgene representatives said the company was planning to keep its current locations in Seattle and its manufacturing facility in Bothell, Wash. There are no indications that those plans have changed.

Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline

Comments

Job Listings on GeekWork

Find more jobs on GeekWork. Employers, post a job here.